Healthcare
Journey Medical Corp(DERM)
Live Price
Offline$6.43
+3.38% today
1Y Change
-7.75%
Window
Jun 25, 2025 โ Jun 22, 2026
- Market Cap
- $140.00M
- Revenue Growth
- +10.2%
- EPS Growth
- +34.7%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 25, 2025 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Journey Medical Corp (DERM) is a Healthcare stock with a market cap of $140.00M and listed on NASDAQ. The stock last traded around $6.43 and down 7.7% across the available one-year price window (Jun 25, 2025 โ Jun 22, 2026). Baseline metrics include revenue growth of +10.2%, EPS growth of +34.7%, a dividend yield of 0.0%. What stands out right now is revenue +10.2%, EPS +34.7%, free cash flow -36.3% with operating margin -13.2% and ROIC -14.3%. Valuation is more restrained than many high-expectation growth names at price/sales 2.3. Stock Foundry combines DERM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+10.2% vs +7.6% peer median
Operating Margin
Below sector median
-13.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +10.2% and EPS at +34.7%, with operating margin around -13.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -9.6% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | +22.4% | +18.9% | +20.8% |
2026 Mar 25, 2026 | +33.3% | -30.0% | -32.1% | -24.9% |
2025 Nov 12, 2025 | -12.5% | -15.3% | -15.7% | -14.3% |
Benchmark Edge
DERM vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
DERM
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
DERM Max Drawdown
-52.59%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for DERM and SPY.
Company Overview
Journey Medical Corp
NASDAQ
Journey Medical Corp is an esteemed biopharmaceutical company focused on the dermatological sector. Its primary function is to develop and commercialize innovative pharmaceutical products that address the unmet medical needs in dermatology. Journey Medical Corp's portfolio includes a wide range of dermatological products designed to treat various conditions, including acne, rosacea, and other skin disorders. The company's emphasis on dermatology allows it to significantly impact the healthcare industry by providing critical treatments that enhance patient care and outcomes. As a player in the biopharmaceutical market, Journey Medical Corp contributes to advancing medical research and development, particularly in skin care solutions. This focus not only enhances its importance in the healthcare sector but also emphasizes the growing need for specialized therapies in dermatology, underscoring its role in improving the quality of life for patients suffering from chronic skin conditions.
- Leadership
- Mr. Claude Maraoui
- Employees
- 58
- Street Address
- 9237 East Via de Ventura Blvd., Suite 105
- Mailing
- Scottsdale, AZ, 85258
- Region
- Scottsdale, AZ, United States
- Last Updated
- May 20, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 2.3
- Price/Book
- 4.0
Growth
- Revenue
- +10.2%
- EPS
- +34.7%
- Free Cash Flow
- -36.3%
Profitability
- Gross Margin
- 59.3%
- Operating Margin
- -13.2%
- Net Margin
- -18.5%
- ROE
- -46.4%
- ROIC
- -14.3%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 1.79
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.